L-Irinotecan + Veliparib


Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

Are you Eligible? (Inclusion Criteria)

Inclusion Criteria:

  • Pathologically confirmed diagnosis of one of any solid tumor
  • Metastatic disease
  • ECOG performance status ≤2 

Exclusion Criteria:

  • Known and confirmed diagnosis of Interstitial Lung Disease
  • Clinically significant GI disorders, including history of small bowel obstruction unless the obstruction was a surgically treated remote episode
  • HIV-positive patients on combination antiretroviral therapy
  • High risk of seizures

Specialty Area(s)